拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.
撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

SUSPENSION OF TRADING

This announcement is made by Cloudbreak Pharma Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Direction from the Securities and Futures Commission

The board of directors of the Company (the "**Board**") announces that the Securities and Futures Commission (the "**Commission**") has on 10 September 2026 directed The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") to suspend trading in the shares of the Company (the "**Shares**") with effect from 9:00 a.m. on 10 September 2026 under section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V of the Laws of Hong Kong) (the "**Direction**"). The Commission has serious concerns that the initial public offering of the Company may have been rigged to create an artificial impression of demand for the Shares. As such, the Commission considers that the suspension is necessary or expedient to maintain an orderly and fair market in the Shares and to protect the interests of the investing public while the Commission's investigation continues.

The Company is seeking legal advice on the Direction and as to how to address and resolve the Commission's concerns. The Company will fully cooperate with the Commission in its investigation and will make further announcement(s) in due course.

The Company confirms that the Group's business operations remain normal, and that there is no material change to the business operations of the Group as at the date of this announcement.

Continued Suspension of Trading

All dealings in the shares of the Company have been suspended by the Stock Exchange as directed by the Commission since 9:00 a.m. on 10 September 2026 and will remain suspended until further notice.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Cloudbreak Pharma Inc.
Dr NI Jinsong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 18 September 2026

As at the date of this announcement, the Board comprises: (i) Dr Ni Jinsong, Mr Dinh Son Van and Dr Yang Rong as executive Directors; (ii) Dr Li Jun Zhi, Mr Cao Xu and Mr Xia Zhidong as non-executive Directors; and (iii) Ms Nie Sijiang, Mr Ma Yiu Ho Peter and Mr Lee Alex Jao Jang as independent non-executive Directors.

* *For identification purposes only*